Evidence map›Paper›PMID 40357376›Full record

ArticleJournal of inflammation research2025

Diagnostic Utility of Pentraxin 3 Expression in Septic Cardiomyopathy: Findings from a Prospective Observational Study.

Na Cui, Xiao-Wei Lv, Teng-Hao Shao, Zhan-Biao Yu, Zhi Chen, Tao Sun, Tie-Min Li, Jin-Wen Zhang, Zhen-Jie Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Na Cui *Department of Critical Care Medicine, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050010, People's Republic of China.
Xiao-Wei Lv *Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Teng-Hao ShaoDepartment of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Zhan-Biao YuDepartment of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Zhi ChenDepartment of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Tao SunDepartment of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Tie-Min LiDepartment of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Jin-Wen ZhangDepartment of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding, 071000, People's Republic of China.
Zhen-Jie HuDepartment of Critical Care Medicine, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, 050010, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study is to investigate the expression levels of Pentraxin 3, PTX3 in patients with septic cardiomyopathy, SCM and evaluate its diagnostic potential for predicting SCM. Methods: A prospective observational study was conducted involving 122 patients diagnosed with septic shock between February 2023 and August 2024. Demographic and clinical data, along with plasma PTX3 concentrations were recorded. Participants were categorized into two groups based on the presence of SCM. PTX3 concentrations and their dynamic changes were compared between the groups. The correlations between PTX3 concentrations and other clinical indicators were analyzed, and the influencing factors associated with SCM development were assessed. The predictive performance of PTX3 for SCM was evaluated using receiver operating characteristic, ROC curves. Results: SCM was identified in 24.6% of the participants. Plasma PTX3 concentrations at admission and on day 3 were significantly higher in the SCM group compared to the non-SCM group, Conclusion: Plasma PTX3 concentrations are markedly elevated in patients with SCM, indicating that PTX3 may serve as a reliable biomarker for the early diagnosis of SCM.

Indexed as

diagnosisPTX3sepsisseptic cardiomyopathyseptic shock

Identifiers

PMID40357376
PMCPMC12067461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.